A digital healthcare intelligence firm, VigiLanz, declared today that its antimicrobial stewardship platform has achieved Meaningful Use Stage 3 (MU3) certification enabling its capability to accumulate and rightly report data around antimicrobial use and resistance. VigiLanz is believed to be one of the 1st to earn Stage 3 certification for use by facilities enrolled in the NHSN (National Healthcare Safety Network) that are needed to start reporting Antimicrobial Use and Antimicrobial Resistance (AUR) data in the year of 2018
VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA, pointing out that drug resistant organism alone infect two million people and claim 23,000 lives in the U.S. per year, while adding $34 billion to yearly healthcare costs. He added, "Unsuitable antibiotic utilization and multidrug resistant organisms are among the deadliest threats facing the healthcare system today. That is why it was so significant to us to earn MU certification for AUR data collection and reporting. It lets us play an active role in dealing this injurious and expensive phenomenon."
AUR data’s submission into the NHSN platform permits clinicians to benchmark their antibiotic usage and organism resistance data nationally to target places of improvement.
6 months were spent by VigiLanz working on updates to its platform in preparation for its certification application. As such, it can rightly gather and report data in the CDA format retroactively to the day of January 1, 2017. Any customer with Dynamic Antimicrobial Stewardship or Dynamic Pharmacy Surveillance modules that is presently sending electronic medication reconciliation information can take benefit of certification without the requirement for extra upgrades, and without incurring any extra charges. VigiLanz also has the means to help clients not yet gathering this information to do so retroactively.
Key part of the VigiLanz' clinical intelligence platform, the antimicrobial stewardship solution uses data collected from the electronic medical record, laboratory, physician order entry and pathology systems of hospital to monitor sufferers in real-time for drug interactions and ineffective or unsuitable antibiotics. Alerts are triggered to verify the clinical pharmacists and other members of the care team to take suitable steps and actions when potential problems are identified.